These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37852006)

  • 1. The Effect of Route of Administration and Vehicle on the Pharmacokinetics of THC and CBD in Adult, Neonate, and Breastfed Sprague-Dawley Rats.
    Soni I; Chinn GA; Halifax JC; Hellman J; Lynch KL; Sall JW
    Cannabis Cannabinoid Res; 2024 Oct; 9(5):e1443-e1451. PubMed ID: 37852006
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
    Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
    Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
    Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
    Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
    Moore CF; Weerts EM
    Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ
    Palazzoli F; Citti C; Licata M; Vilella A; Manca L; Zoli M; Vandelli MA; Forni F; Cannazza G
    J Pharm Biomed Anal; 2018 Feb; 150():25-32. PubMed ID: 29202305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cannabinoid plasma concentration, maternal health, and cytokine levels in a rat model of prenatal Cannabis smoke exposure.
    Black T; Baccetto SL; Barnard IL; Finch E; McElroy DL; Austin-Scott FVL; Greba Q; Michel D; Zagzoog A; Howland JG; Laprairie RB
    Sci Rep; 2023 Nov; 13(1):21070. PubMed ID: 38030657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
    Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol modulation of antinociceptive tolerance to Δ
    Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM
    Psychopharmacology (Berl); 2018 Nov; 235(11):3289-3302. PubMed ID: 30238130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
    Deiana S; Watanabe A; Yamasaki Y; Amada N; Arthur M; Fleming S; Woodcock H; Dorward P; Pigliacampo B; Close S; Platt B; Riedel G
    Psychopharmacology (Berl); 2012 Feb; 219(3):859-73. PubMed ID: 21796370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral Effects of Vaporized Delta-8 Tetrahydrocannabinol, Cannabidiol, and Mixtures in Male Rats.
    Durbin DJ; King JM; Stairs DJ
    Cannabis Cannabinoid Res; 2024 Apr; 9(2):601-611. PubMed ID: 36802211
    [No Abstract]   [Full Text] [Related]  

  • 13. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents.
    Manwell LA; Ford B; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):112-9. PubMed ID: 24956154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study.
    Varadi G; Zhu Z; Crowley HD; Moulin M; Dey R; Lewis ED; Evans M
    Adv Ther; 2023 Jan; 40(1):282-293. PubMed ID: 36308640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of escalating cannabinoid doses in healthy cats.
    Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
    J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant.
    Ravula A; Chandasana H; Setlow B; Febo M; Bruijnzeel AW; Derendorf H
    J Pharm Biomed Anal; 2018 Oct; 160():119-125. PubMed ID: 30077950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats.
    Javadi-Paydar M; Nguyen JD; Kerr TM; Grant Y; Vandewater SA; Cole M; Taffe MA
    Psychopharmacology (Berl); 2018 Sep; 235(9):2541-2557. PubMed ID: 29907926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
    Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
    Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products.
    Berthold EC; Kamble SH; Kanumuri SRR; Kuntz MA; Senetra AS; Chiang YH; McMahon LR; McCurdy CR; Sharma A
    Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):427-435. PubMed ID: 37337087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.